Trials / Completed
CompletedNCT05664828
Efficacy of SN132D in Patients With Suspected Endometriosis
A Phase IIa, Single Centre, Open Label, Proof of Concept Study Concerning Efficacy of the Novel Intravenous Contrast Agent SN132D in Patients With Suspected Endometriosis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Spago Nanomedical AB · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase IIa, open-label, non-randomised and non-placebo-controlled study. The study is designed to evaluate the diagnostic value and safety of a single intravenous dose of SN132D in up to 18 participants with suspected endometriosis. Magnetic resonance imaging (MRI) will be performed pre- and post-infusion of SN132D.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SN132D | Manganese-based macromolecular MRI contrast agent |
Timeline
- Start date
- 2022-11-17
- Primary completion
- 2023-06-20
- Completion
- 2023-09-12
- First posted
- 2022-12-27
- Last updated
- 2023-12-12
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT05664828. Inclusion in this directory is not an endorsement.